ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,345Medicare Part D Prescriptions Filled, Including Refills

Rank: 102 out of 670

$718K Total Retail Price of All Prescriptions

Rank: 92 out of 670

290 Patients Receiving at Least One Drug in Part D
51%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in West Virginia
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

6% of this provider’s 290 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

0% of this provider’s 6,649 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$63 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

39 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in West Virginia
CRESTOR 752 370 1 18
LISINOPRIL 586 388 2 3
METFORMIN HCL 352 233 3 8
LEVOTHYROXINE SODIUM 345 216 4 2
OMEPRAZOLE 324 124 5 5
AMLODIPINE BESYLATE 319 209 6 7
METOPROLOL SUCCINATE 313 216 7 12
LISINOPRIL-HYDROCHLOROTHIAZIDE 300 147 8 27
FLUTICASONE PROPIONATE 268 135 9 37
HYDROCHLOROTHIAZIDE 253 186 10 10
FENOFIBRATE 227 85 11 64
FUROSEMIDE 225 152 12 6
SIMVASTATIN 223 133 13 4
ZETIA 221 100 14 66
ATORVASTATIN CALCIUM 201 144 15 15
RANITIDINE HCL 199 103 16 25
POTASSIUM CHLORIDE 174 128 17 16
TRAMADOL HCL 166 93 18 21
METOPROLOL TARTRATE 163 127 19 9
NEXIUM 159 106 20 14
MELOXICAM 159 104 20 33
GLIMEPIRIDE 147 100 22 32
PROAIR HFA 146 93 23 28
CLOPIDOGREL 144 86 24 24
HYDROCODONE-ACETAMINOPHEN 106 54 S3 25 1
TAMSULOSIN HCL 103 55 26 30
ACTOS 99 64 27 105
VITAMIN D2 96 43 28 160
SPIRIVA 95 53 29 51
IBUPROFEN 95 28 29 50
NIASPAN 94 44 31 116
CARVEDILOL 90 52 32 29
ALENDRONATE SODIUM 89 86 33 43
GLIPIZIDE 88 58 34 67
PLAVIX 87 58 35 34
NAPROXEN 87 23 35 81
ATENOLOL 83 75 37 17
BACLOFEN 76 20 38 129
ZOLPIDEM TARTRATE 70 52 39 23
GABAPENTIN 70 28 39 11
CITALOPRAM HBR 70 44 39 20
WARFARIN SODIUM 67 52 42 13
ALLOPURINOL 67 33 42 38
ADVAIR DISKUS 65 33 44 42
DILTIAZEM 24HR CD 62 62 45 109
NITROSTAT 61 33 46 155
SERTRALINE HCL 57 39 47 22
CYMBALTA 54 24 48 36
DIOVAN 52 36 49 48
NOVOLOG FLEXPEN 52 47 49 193
LIPITOR 51 32 51 156
LANTUS SOLOSTAR 51 41 51 98
DILTIAZEM 24HR ER 51 37 51 122
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 17, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.